Patent ID: 8603972

Claim:
A glucagon-like peptide (GLP-1) analog having a modification of at least one non-proteogenic amino acid residue in positions 7 and/or 8 relative to the sequence GLP-1(7-37) (SEQ ID No 1), where said analog is acylated with a moiety to the lysine residue in position 37 or 38, and where said moiety comprises at least two acidic groups, wherein one acidic group is attached terminally, and wherein the GLP-1 analog is of formula I wherein Xaa 7 is L-histidine, imidazopropionyl, α-hydroxy-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, Nα-acetyl-histidine, N α -formyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine Xaa 8 is Ala, Gly, Val, Leu, Ile, Thr, Ser, Lys, Aib, (1-aminocyclopropyl)carboxylic acid, (1-aminocyclobutyl)carboxylic acid, (1-aminocyclopentyl)carboxylic acid, (1-aminocyclohexyl)carboxylic acid, (1-aminocycloheptyl)carboxylic acid, or (1-aminocyclooctyl)carboxylic acid; Xaa 16 is Val or Leu; Xaa 18 is Ser, Lys or Arg; Xaa 19 is Tyr or Gln; Xaa 20 is Leu or Met; Xaa 22 is Gly, Glu or Aib; Xaa 23 is Gln, Glu, Lys or Arg; Xaa 25 is Ala or Val; Xaa 26 is Lys, Glu or Arg; Xaa 27 is Glu or Leu; Xaa 30 is Ala, Glu or Arg; Xaa 33 is Val or Lys; Xaa 34 is Lys, Glu, Asn or Arg; Xaa 35 is Gly or Aib; Xaa 36 is Arg, Gly or Lys, or is absent; Xaa 37 is Gly, Ala, Glu, Pro, Lys, Asn or is absent; Z is OH or NH 2 B is an acidic group selected from where l is 12, 13, 14, 15, 16, 17, 18, 19 or 20, U′ is a spacer selected from wherein n is 1, 2 or 3 and s is 0, 1, 2, or 3.